The global antidote market size was valued at USD 2.16 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 7.60% from 2024 to 2030. Increasing number of occupational poisoning, growing incidence of snake bites and rising incidences of drug overdoses are key factors driving the demand for antidote. For instance, according to a NCBI research article published in 2023, about 106,699 fatalities were reported due to drug overdose in 2021, in the U.S.Furthermore, increased prevalence of medical conditions necessitating the need of antidotes, such as pneumonia prophylaxis, smoking cessation, toxoplasmosis, opioid overdose, reversal of opioid sedation, trichotillomania, and sedation reversal, is driving the growth of the market.
Growing strategic initiatives by key operating players in the market is expected to offer lucrative opportunities during the forecast period. For instance, in October 2021, Hikma Pharmaceuticals PLC, donated 50,000 dosesNaloxone HCl Injection to expand the company’s non-profit access for the treatment of opioid overdoses. This initiative was anticipated to addresses health issues in underserved communities across the globe, thereby contributing for the market expansion.
Additionally, increasing awareness and research programs on antidote by major companies and governments are anticipated to accelerate the market growth during the forecast period. For instance, in May 2022, a virtual training workshop was conducted by the WHO for coordinated antidote procurement in the South-East Asia Region to secure the supply of essential antidote for poisoning emergencies. These initiatives aim to enhance the understanding of antidote and drugs, ultimately driving market expansion.
Furthermore, increasing incidence of occupational poisoning across the globe is projected to propel the market growth during the forecast period. For instance, according to the BMC Public Health global study approximately 44%, 860 million farmers are annually poisoned by pesticides every year. Moreover the increasing prevalence of drug over dose is also expected to drive the market growth. For instance, according to the National Safety Council, around 98,268 people in the U.S. died to drug over dose in 2021. Therefore, the aforementioned factors are likely to boost the market growth.
Chemical antidote segment held the largest market share of 42.89% in 2023. Chemical antidotes offer targeted and rapid treatment for specific toxins, ensuring effectiveness and minimizing complications. Administered by trained professionals, they act immediately, reducing long-term health effects and providing predictable emergency outcomes. Their precise dosing and customization enhance their therapeutic value, making them indispensable in specialty care settings for countering poisoning and toxic exposures. Moreover, key players in the market are offering novel chemical antidote for treatment of various conditions including drug overdose. For instance, Hikma Pharmaceuticals PLC, offers Narcan (naloxone HCl) 4mg for the treatment of opioid overdoses. These factors are fueling the segment.
Pharmacological segment is predicted to grow with significant CAGR over the forecast period. Majority of existing antidote only partially counteract the effects of toxins. They target the body's tissues, inducing symptoms that are completely opposite to those caused due to poisoning poison. Compared to physical and chemical antidote, pharmacological antidote pose no harm. Cyanide and amyl nitirate, barbiturates and picrotoxin or amphetamine are few available pharmacological antidotes. For instance, ACHE inhibitor- morphine is a pharmacological antidote that facilitates rapid and complete elimination of toxins by restoration of normal function. These factors collectively contribute to the robust growth of the antidote market.
Injectable segment held the largest market share of 42.38% in 2023. Antidote injections offer quick, precise, and targeted treatment by effectively countering toxins or drug effects. They counteract the toxic effects of various substances, making them invaluable in critical situations. In addition, they directly target the underlying toxicity in cases of poisoning, overdose, or toxic exposures. Antidote injections are highly specific, specifically designed to neutralize the effects of particular toxins, ensuring precise and effective treatment. Their use provides a standardized approach, reducing the risk of errors in dosage or administration. When typically administered by healthcare professionals, antidote injections play a crucial role in preventing or mitigating severe organ damage that might occur due to toxic exposures. Such capabilities are driving the segment growth.
Oral segment is expected to grow at a significant CAGR during the study period. Oral delivery of antidotes has gained attention attributed to the high acceptability associated with the dosage form. Oral antidotes provide several advantages, such as reduced pain and discomfort as they eliminate the need for injections, making them more acceptable to patients. In some cases, patients can self-administer oral antidotes, which is crucial when immediate treatment is required before professional medical help is available. They also present a lower risk of infection, making them safer for non-medical personnel to handle. Therefore, the aforementioned factors are anticipated to propel the segment growth over the study period.
Hospital pharmacies segment held the largest share of 53.69% of the antidote market in 2023. This growth can be attributed to various factors, including the enhanced accessibility of antidote treatment options and medications offered through hospital pharmacies. Patients are experiencing greater convenience in obtaining their prescribed medications and associated products from hospital pharmacies, which is fueling the demand for these services. Furthermore, the increasing involvement of hospital pharmacies in delivering patient education and offering advice on antidote treatment regimens is expected to play a major role in the expansion of this segment.
Online pharmacies segment is predicted to grow with significant CAGR over the forecast period. The ease, adaptability, and convenience offered by online medication purchases play a significant role in propelling this segment. Moreover, the discounts provided by online pharmacies serve as a compelling incentive for patients to opt for online medication purchases. They also provide valuable information on antidotes, potential side effects, and interactions. In addition, home delivery services ensure that antidotes are conveniently delivered to customers' doorsteps. Online pharmacies are especially beneficial for those in rural or remote areas with limited access to traditional pharmacies, offering essential healthcare access is further contributing to the segment growth.
Hospitals segment accounted the highest share of 37.24% on the antidote market. The number of antidote treatments conducted in hospitals surpasses that of any other healthcare facility, primarily due to favorable reimbursement systems and the prevalence of hospitals as primary care providers in many developing countries. For instance, the rate of hospitalization for psychodysfunctional and narcotic poisoning in geriatric patients increased by 3.97 fold from 5.03 in 1999 to 25.00 in 2020 per 100,000 individuals. Additionally, the increasing influx of individuals, particularly in rural regions, and the ease of access to hospitals, are expected to elevate the need for antidote in hospitals further. Therefore, this surge in demand is set to drive growth within this segment.
Specialty care segment is expected have substantial growth during the projected timeframe. Antidotes are an essential component of specialty care, ensuring rapid and effective treatment of poisoning and toxic exposures in various medical specialties. They are used in toxicology, emergency medicine, ICUs, oncology, infectious disease, anesthesiology, cardiology, and pediatrics among others. Thus, broad applications of antidote in specialty care is anticipated to propel the segment in the near future.
North America accounted for the largest revenue share of 33.57% in 2023 attributed to various factors such as a rise in burden of poisoning and presence of major operating players. For instance, according to the NCPC, estimates in 2021, 1 poison exposure case is reported in every 15 seconds in the U.S. poison control centers. Some of the major players operating in the antidote market are Pfizer Inc., Endo International plc, and Baxter International, Inc. The presence of these leading players in the antidote market is expected to increase the availability of antidote in the region. In addition, increasing healthcare spending and improved medical facilities is also driving regional growth.
Asia Pacific is estimated to grow at the fastest CAGR during the forecast period attributed to local presence of leading antidote companies and increase in R&D investment. There has been an increase in R&D investment by APAC countries, such as China and Japan, which has led to a growth in development of antidote. Moreover, the cost of clinical trials in developing economies such as China and India is lower than that in developed economies. In addition, there has been an increase in the population's disposable income in developing economies, such as India and China. High incidence of insecticide poisoning in this region has increased the demand for antidotes in the region. For instance, according to a 2023 NCBI reach article, approximately 76,000 organophosphate poisoning cases are reported in India every year. All the aforementioned factors are expected to boost the market.
Companies are undertaking strategic initiatives such as product collaborations, geographic expansion, and strategic agreements for product portfolio expansion to maximize their market share. To sustain their presence in the market, industry players are further concentrating on collaborations, acquisitions, mergers and product approval. For instance, in March 2023, EMERGENT, received the U.S. FDA approval for Narcan, first over-the-counter nasal spray for the treatment of opioid overdose. Such, initiatives are expected to boost the antidote market during the review period.
Report Attribute |
Details |
Market size value in 2024 |
USD 2.31 billion |
Revenue forecast in 2030 |
USD 3.58 billion |
Growth rate |
CAGR of 7.60% from 2024 to 2030 |
Base year for estimation |
2023 |
Historical data |
2018 - 2022 |
Forecast period |
2024 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2024 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, trends |
Segments covered |
Type, route of administration, distribution channel, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia, UAE; Kuwait |
Key companies profiled |
Pfizer Inc.; Hikma Pharmaceuticals PLC; Dr. Reddy’s Laboratories Ltd; Mylan N.V.; Fresenius Kabi AG; Zydus Lifesciences Ltd.; Endo International plc; Novartis AG; Baxter International, Inc., Emergent BioSolutions Inc. |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented antidote market on the basis of type, route of administration, distribution channel, end use, and region.
Type Outlook (Revenue, USD Million, 2018 - 2030)
Chemical Antidote
Physical Antidote
Pharmacological Antidote
Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
Oral
Topical
Injectable
Others
Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
End Use Outlook (Revenue, USD Million, 2018 - 2030)
Hospital
Homecare
Specialty Clinics
Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. The global antidote market size was valued at USD 2.16 billion in 2023 and is expected to reach USD 2.31 billion in 2024.
b. The global antidote market is expected to expand at a compound annual growth rate (CAGR) of 7.60% from 2024 to 2030 to reach USD 3.58 billion by 2030.
b. The chemical antidote segment held the largest market share of 42.88% in 2023. Chemical antidotes offer targeted and rapid treatment for specific toxins, ensuring effectiveness and minimizing complications.
b. Some key players operating in the antidote market include Pfizer Inc.; Hikma Pharmaceuticals PLC; Dr. Reddy’s Laboratories Ltd; Mylan N.V.; Fresenius Kabi AG; Zydus Lifesciences Ltd.; Endo International plc; Novartis AG; Baxter International, Inc., EMERGENT
b. Key factors that are driving the market growth include increasing number of occupational poisoning, growing incidence of snake bites, and rising incidences of drug overdoses
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."